TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 471		U.S. Patent Application Publication U.S. 2004/0214829	ALC61317-ALC61331		402-403			
DTX 472		U.S. Patent Application Publication 2005/0026924 A1	ALC61332-ALC61347		402-403			
DTX 473		M. Z. Southard, "Transport Mechanisms of Sparingly Soluble Acid Dissolution in Aqueous Solution of Variable pH." Ph.D. Dissertation to the University of Kansas, 1988. Co-advised with K. Himmelstein and H. Rosson.			402-403			
DTX 474		S. Neervannan, "Dissolution Mechanisms for Sparingly Soluble Compounds Under Laminar Hydrodynamic Conditions." Ph.D. Dissertation to the University of Kansas, 1994.			402-403			
DTX 475		Dissolution Kinetics if Carboxylic Acids I: Effect of PH under Unbuffered Conditions. K.G. Mooney, M. Mintun, K.J. Himmelstein and V.J. Stella, J. Pharm. Sci., 70, 13-22 (1981).			402-403			
DTX 476		Prodrugs as Drug Delivery Systems XXI. Preparation, Physicochemical Properties and Bioavailability of a Novel Water-			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 1 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Soluble Prodrug Type for Carbamazepine, H. Bundgaard, M. Johansen, V.J. Stella and M. Cortese, Int. J. Pharm., 10, 181-192 (1982).						
DTX 477		Phenindione Solubility in Mixed Organic Solvents: Analysis of the Role of Specific Hydrogen and Non-Hydrogen Bonding Interactions. J.D. Pipkin and V.J. Stella, Int. J. Pharm., 14, 263-77 (1983).			402-403			
DTX 478		Equilibria and Kinetics of Ebifuramin (NSC-201047), and Azomethine Containing Structure Exhibiting a Reversible Degradation Step in Acidic Solutions. R.J. Prankerd and V.J. Stella, Int. J. Pharmac., 52 71-78 (1989).			402-403			
DTX 479		Preformulation Solubility and Kinetic Studies of 2',3'-Dideoxypurine Nucleosides: potential anti-AIDS agents. B.D. Anderson, M.B. Wygant, T-X. Xiang, W.A. Waugh, and V.J. Stella, Int. J. Pharmac., 45, 27-37 (1988).			402-403			
DTX 480		Stability and Solubility of 2-Chloro-2',3'-			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 2 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		dideoxyadenosine. L.A. Al-Razzak, and V.J. Stella, Int. J. Pharmac., 60, 53-60 (1990).						
DTX 481		Evolution of Formulation Practices, V.J. Stella, Drug Dev. Ind. Pharm., 16, 2627-2633 (1990).			402-403			
DTX 482		Factors Influencing the Precipitation time of Phenytion in the presence of DDMS, one of its Prodrugs. D.G. Muller, V.J. Stella, and A.P. Lotter, Int. J. Pharmac., 75, 201-209 (1991).			402-403			
DTX 483		Rapid Expansion from Supercritical Solutions: Application to Pharmaceutical Processess, E.M. Phillips and V.J. Stella, Int. J. Pharmac., 94, 1-10 (1993).			402-403			
DTX 484		The Effect of SBE4-B-CD on I.V. Methylprednisolone Pharmacokinetics in Rats: Comparison to a co-Solvent Solution and Two Water Soluble Prodrugs, V.J. Stella, H.Y. Lee and D.O. Thompson, Int. J. Pharm., 120, 189-195 (1995).			402-403			
DTX 485		The Effect of SBE4-B-CD on I.M.			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 3 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Prednisolone Pharmacokinetics and Tissue Damage in Rabbits: comparison to a Co-Solvent Solution and a Water Soluble Prodrug, V.J. Stella, H.Y. Lee and D.O. Thompson, Int. J. Pharm., 120, 197-204 (1995).						
DTX 486		Effect of SBE4-B-CD, a Sulfobutyl Ether B-Cyclodextrin, on the Stability and Solubility of O6-Benzylguanine (NSC-637037) in Aqueous Solutions, B.A. Gorecka, D.S. Bindra, Y.D. Sanzgiri and V.J. Stella, Int. J. Pharm., 125, 55-61 (1995).			402-403			
DTX 487		The Use of (SBE) 7M-B-CD (Captisol®) as a Solubilizing and Osmotic Agent for Controlled and Complete Oral Delivery of Poorly Waters Soluble Drugs, V.J. Stella, K. Uekama, T. Irie, V.M. Rao, E.A. Zannou, R.A. Rajewski, S. Shiraishi, and K. Okimoto, in Proceedings of the 9th International Symposium on Cyclodextrins, Santiago de Compostela, Spain, J.J. Torres Labadeira and J.L.			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 4 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Vila Jato (Eds), Kluwer Publishing, 459-462 (1999).						
DTX 488		Influence of SBE-y-CD ethylation on 9-NO2-Paullone Solubilization. S. Silchenko, S. Tongiani, and V.J. Stella. Proceedings of the 12th International Cyclodextrin Symposium, Montpellier, France 375-378 (2004).			402-403			
DTX 489		Pro-Drugs: An Overview and Definition. V. Stella. Chapter 1, Book #14 of the American Chemical Society Symposium Series (Pro-Drugs Novel Drug Delivery System, T. Higuchi and V. Stella, eds.) 1975.			402-403			
DTX 490		Fundamentals of Drug Stability and Compatibility. Valentino J. Stella, in "Handbook of Injectable Drugs", L. Trissel, ed., American Society of Hospital Pharmacists, pp. XI-XXII (1986).			402-403			
DTX 491		My Mentors. V.J. Stella, J. Pharm. Sci., 90, 969-978 (2001).			402-403			
DTX 492		Oral Controlled Release of Poorly Water Soluble Drugs Utilizing Captisol® as			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 5 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		both a Solubilizer and Osmotic Agent, V.J. Stella, R. Rajewski, K. Okimoto, K. Uekama, T. Irie, S. Shiraishi, E. Zannou and V. Rao, Proceedings of The 27th International Symposium on Controlled Release of Bioactive Materials, Paris, France, July 2000.						
DTX 493		U.S. Patent No. 4,163,058			402-403			
DTX 494		U.S. Patent No. 5,134,127			402-403			
DTX 495		U.S. Patent No. 5,833,891			402-403			
DTX 496		U.S. Patent No. 5,985,856			402-403			
DTX 497		U.S. Patent No. 6,204,257			402-403			
DTX 498		U.S. Patent application 2001/0025035,			402-403			
DTX 499		U.S. Patent No. 5,376,645			402-403			
DTX 500		U.S. Patent No. 5,833,891			402-403			
DTX 501		U.S. Patent No. 5,985,856			402-403			
DTX 502		U.S. Patent No. 6,204,257			402-403			
DTX 503		U.S. Patent No. 6,451,776			402-403			
DTX 504		Jumaa M, Chimilio L, Chinnaswamy S, Silchenko S, Stella VJ. Degradation of NSC-281612 (4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 6 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		methyl-benzaldehyde), an experimental antineoplastic agent: effects of pH, solvent composition, (SBE)7m-beta-CD, and HP-beta-CD on stability. J Pharm Sci. 2004 Mar;93(3):532-9. PMID: 14762892						
DTX 505		Rao VM, Stella VJ. When can cyclodextrins be considered for solubilization purposes? J Pharm Sci. 2003 May;92(5):927-32. PMID: 12712411			402-403			
DTX 506		Stella VJ, Rao VM, Zannou EA, Zia V V. Mechanisms of drug release from cyclodextrin complexes. Adv Drug Deliv Rev. 1999 Mar 1;36(1):3-16. PMID: 10837705			402-403			
DTX 507		Ma DQ, Rajewski RA, Stella VJ. New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD. Int J Pharm. 1999 Nov 5;189(2):227-34. PMID: 10536251			402-403			
DTX 508		Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2.			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 7 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J Pharm Sci. 1999 Sep;88(9):922-7. PMID: 10479355						
DTX 509		Stella VJ, Martodihardjo S, Rao VM. Aqueous solubility and dissolution rate does not adequately predict in vivo performance: a probe utilizing some N-acyloxymethyl phenytoin prodrugs. J Pharm Sci. 1999 Aug;88(8):775-9. PMID: 10430541			402-403			
DTX 510		Stella VJ, Martodihardjo S, Terada K, Rao VM. Some relationships between the physical properties of various 3-acyloxymethyl prodrugs of phenytoin to structure: potential in vivo performance implications. J Pharm Sci. 1998 Oct;87(10):1235-41. Erratum in: J Pharm Sci 1999 Oct;88(10):1100. PMID: 9758683			402-403			
DTX 511		Medlicott NJ, Foster KA, Audus KL, Gupta S, Stella VJ. Comparison of the			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 8 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		effects of potential parenteral vehicles for poorly water soluble anticancer drugs (organic cosolvents and cyclodextrin solutions) on cultured endothelial cells (HUV-EC). J Pharm Sci. 1998 Sep;87(9):1138-43. PMID: 9724567						
DTX 512		Narisawa S, Stella VJ. Increased shelf-life of fosphenytoin: solubilization of a degradant, phenytoin, through complexation with (SBE)7m-beta-CD. J Pharm Sci. 1998 Aug;87(8):926-30. PMID: 9687335			402-403			
DTX 513		Stella VJ, Rajewski RA. Cyclodextrins: their future in drug formulation and delivery. Pharm Res. 1997 May;14(5):556-67. Review. PMID: 9165524			402-403			
DTX 514		Rajewski RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996 Nov;85(11):1142-69. Review. PMID: 8923319			402-403			
DTX 515		Jarvinen K, Jarvinen T, Thompson DO,			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 9 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Stella VJ. The effect of a modified beta-cyclodextrin, SBE4-beta-CD, on the aqueous stability and ocular absorption of pilocarpine. Curr Eye Res. 1994 Dec;13(12):897-905. PMID: 7720398						
DTX 516		Southard MZ, Green DW, Stella VJ, Himmelstein KJ. Dissolution of ionizable drugs into unbuffered solution: a comprehensive model for mass transport and reaction in the rotating disk geometry. Pharm Res. 1992 Jan;9(1):58-69. PMID: 1589411			402-403			
DTX 517		Stella VJ. Chemical and physical bases determining the instability and incompatibility of formulated injectable drugs. J Parenter Sci Technol. 1986 Jul-Aug;40(4):142-63. Review.. PMID: 3534205			402-403			
DTX 518		Aunins JG, Southard MZ, Myers RA, Himmelstein KJ, Stella VJ. Dissolution of carboxylic acids. III: The effect of polyionizable buffers. J Pharm Sci. 1985 Dec;74(12):1305-16. PMID: 4087198			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 10 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 519		Stella VJ, Charman WN, Naringrekar VH. Prodrugs. Do they have advantages in clinical practice? Drugs. 1985 May;29(5):455-73. Review. PMID: 3891303 Varia SA, Schuller S, Sloan KB, Stella VJ. Phenytoin prodrugs III: water-soluble prodrugs for oral and/or parenteral use. J Pharm Sci. 1984 Aug;73(8):1068-73. PMID: 6491911			402-403			
DTX 520		Stella VJ, Mooney KG, Pipkin JD. Dissolution and ionization of warfarin. J Pharm Sci. 1984 Jul;73(7):946-8. PMID: 6470958			402-403			
DTX 521		Mooney KG, Rodriguez-Gaxiola M, Mintun M, Himmelstein KJ, Stella VJ. Dissolution kinetics of phenylbutazone. J Pharm Sci. 1981 Dec;70(12):1358-65. PMID: 7320853			402-403			
DTX 522		C.G. Wilson, Olejnik and J.G. Hardy (1983) "Precorneal drainage of polyvinyl alcohol solutions in the rabbit assessed by gamma scintigraphy" J. Pharm.			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 11 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Pharmacol. 35: 451-4.						
DTX 523		N. Washington and C.G. Wilson (1986) "Antacids: Physiology versus Pharmaceutics" Int. J. Pharmaceut. 28: 249-260.			402-403			
DTX 524		Pharmacokinetic Modeling using STELLA on the Apple MacIntosh N. Washington, C. Washington and C.G. Wilson Pub., Ellis Horwood, Chichester, 1992			402-403			
DTX 525		N. Washington and C.G. Wilson (1995) "Physiological Factors affecting drug delivery and availability" Encyclopedia of Pharmaceutical Technology Vol. 17, 137-69 (1995).			402-403			
DTX 526		C.G. Wilson (2000) "Role of Excipients in Colonic Drug Delivery" In 'Recent advances in pharmaceutical, cosmetic and food excipients. Ed AA Hincal and H.J. de Jong, Editions SanteParis, pp 177-186			402-403			
DTX 527		O. Olejnik, C.G. Wilson & Y.P. Zhu (2000). "Non-aqueous vehicles in ocular drug delivery". Proc. 3rd Int. Symposium			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 12 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		on Ocular Pharmacology & Pharmaceutics (ISSOPP) p 24.						
DTX 528		Semenova E.M., Cooper A., Wilson C.G., Converse C.A. (2001). Cyclodextrins: Solutions for insolubility of vitamin A. British Pharmaceutical Conference Science Proceedings 2001: 126.			402-403			
DTX 529		C.G. Wilson (2000). Encyclopedia of Controlled drug delivery. (book review). Br. J. clin. Pharmacol. 49, 91-2.			402-403			
DTX 530	05/16/05	Declaration of V. Stella						
DTX 531		List of Expert Cases Worked on by Dr. Gordon Amidon			402-403, 802, 702-703			
DTX 532		Chart: Solubility of Brimonidine Tartrate			402-403, 802, 702-703, F.R.C.P. 37			
DTX 533		Graph: PVA Vehicle Solubility Profiles			402-403, 802, 702-703, F.R.C.P. 37			
DTX 534		Exerpts from Notebook 12079 for Brimonidine Tartrate Project No. 22-556	ALC61288A-ALC61291A		Object to use by Alcon only, 402-403, 802			
DTX 535		Letter from Woodcock to Mahn re Docket No. 02P-0469/CP1, dated 05/21/2003	ALC61292A-ALC61306		402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 13 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 536		Vial Containing 0.15% Brimonidine Tartrate at pH 7.4, no Povidone			402-403, 702-703, 901			
DTX 537		Kramer and Flynn, 1972, Solubility and Organic Hydrochlorides, J. Pharm. Sci. 61(12): 1896-1904			402-403			
DTX 538		Kostenbauder et al., 1953, A Buffer System for Ophthalmic Solutions of Sodium Suflonamides, J. Am. Pharm. Assoc. Vol. XLII (4): 210-213			402-403			
DTX 539		Amidon et al., 1995, A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability, Pharm. Res. 12(3): 413-420			402-403			
DTX 540		McNamara and Amidon, 1986, Dissolution of Acidic and Basic Compounds from the Rotating Disk: Influence of Convective Diffusion and Reaction, J. Pharm. Sci. 75(9): 858-868			402-403			
DTX 541		Vadnere et al., 1984, Thermodynamic Studies on the gel-sol transition of some pluronic polyols, Inl. J. Pharm. 22: 207-			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 14 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		218						
DTX 542		Amidon and Williams, 1982, A solubility equation for non-electrolytes in water, Intl. J. Pharm. 11: 249-256			402-403			
DTX 543		Amidon and Anik, 1980, Hydrophobicity of Polcyclic Aromatic Compounds. Thermodynamic Partitioning Analysis, J. Phys. Chem. 84(9): 970-974			402-403			
DTX 544		Amidon et al., 1980, Improvng Intestinal Absorption of Water-Insoluble, Compounds: A Membrane Metabolism Strategy, J. Pharm. Sci. 69(12): 1363-1368			402-403			
DTX 545		Williams and Amidon, 1984, Excess Free Energy Approach to the Estimation of Solubility in Mixed Solvent Systems I: Theory, J. Pharm. Sci. 73(1): 9-13			402-403			
DTX 546		Valvani et al., 1976, Solubility of Nonelectrolytes in Polar Solvents. VI. Refinements in Molecular Surface Area Computations, J. Phys. Chem. 80(8): 829-835			402-403			
DTX 547		Amidon et al., 1975, Solubility of			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 15 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Nonelectrolytes in Polar Solvents. V. Estimation of the Solubility of Aliphatic Monofunctional Compounds in Water Using a Molecular Surface Area Approach, J. Phys. Chem. 79(21): 2239-2246						
DTX 548		Amidon et al., 1974, Solubility of Nonelectrolytes in Polar Solvents II: Solubility of Aliphatic Alcohols in Water, J. Pharm. Sci. 63(12):1858-1866			402-403			
DTX 549		Yalkowsky et al, 1972, Solubility of Nonelectrolytes in Polar Solvents			402-403			
DTX 550		J. Neter, W. Wasserman, M. Kutner, Applied Linear Statistical Models: Regression, Analysis of Variance, and Experimental Designs, (2nd Ed., 1985, Richard Irwin, Inc.)			402-403			
DTX 551		N. R. Draper and H. Smith, Applied Regression Analysis, (2nd Ed., 1981, John Wiley & Sons Inc.)			402-403			
DTX 552		Wayne Daniel, Biostatistics: A Foundation for Analysis in the Health Sciences, (4th Ed., 1987, John Wiley &			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 16 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Sons)						
DTX 553		SigmaStat 3.1, Chapter 8, pp. 203-328			402-403			
DTX 554		SigmaStat 3.1, Chapter 11, pp. 465-668			402-403			
DTX 555		A. T. Florence and D. Attwood, Physiochemical Principles of Pharmacy, (2nd Ed., Chapman and Hall)			402-403			
DTX 556		Remington's Pharmaceutical Sciences (17th Ed., 1985, Mark Publishing Co.) Chapters 10, 16, and 17			402-403			
DTX 557		Martin, Physical Pharmacy, (4th Ed., 1993, Lea & Febiger) Chapters 5, 6, 7, 8, 10, and 20			402-403			
DTX 558		W.O. Foye et al, 1995, Principles in Medicinal Chemistry 4th ed. pp. 16-24			402-403			
DTX 559		Krebs, 1945, J. Chem. Soc. 593			402-403			
DTX 560		Higuchi, 1949, Pharmaceutical Coding and Dispersing (R. Lyman Ed.) p. 179			402-403			
DTX 561		Yalkowsky, Techniques of Solubilization of Drugs, (1981, M. Dekker)			402-403			
DTX 562		Amidon Graph of Wilson Data "Solubility v. pH for Brimonidinr (0 and 1.2% PVP)	ALC61350		402-403, 702-703, 802			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 17 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 563		Amidon Printout Concerning Wilson Data	ALC61351-ALC61352		402-403, 702-703, 802			
DTX 564		Sigma-Aldrich Catalog Product Information on PVP360			402-403			
DTX 565		Sigma-Aldrich Catalog Specification Sheet on PVP360			402-403			
DTX 566		The Merck Index: Brimonidine			402-403			
DTX 567		GraphPad Prism 4 Software: Prism Simplifies Statistics						
DTX 568		GraphPad Prism Version 4.0 Statistics Guide 1999-2003						
DTX 569		GraphPad Prism Version 4.0 Statistics Guide 1999-2005						
DTX 570		Model IQ150 Handheld pH/mV/Temperature Meter Instruction Manual						
DTX 571		Wilson et al., 1998, Ocular contact time of a carbomer gel (GelTears) in humans, Br. J. Ophthalmol 82: 1131-1134			402-403			
DTX 572		Snibson et al., 1992, Ocular Surface Residence Times of Artificial Tear Solutions, Cornea 11(4): 288-293			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 18 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 573		Wilson et al, 2001, Opthalmic Drug Delivery (Drug Delivery and Targeting for Pharmacists and Pharmaceutical Scientists, edited by A. Hillery, A. Lloyd and J. Swarbrick)			402-403			
DTX 574		Greaves and Wilson, 1993, Treatment of diseases of the eye with mucoadhesive delivery systems, Advanced Drug Delivery Reviews 11: 349-383			402-403			
DTX 575		Encyclopedia of Pharmaceutical Technology Vol. 12, (Ed. Swarbrick and Boylan), pp. 137-166			402-403			
DTX 576		Wilson, 2004, Topical drug delivery in the eye, Exp. Eye Res. 78: 737-7432			402-403			
DTX 577		Gurny et al., 1987, Design and Evaluation of Controlled Release Systems for the Eye, J. Controlled Release 6: 367-373			402-403			
DTX 578		Martin et al., 1998, Chitosan based hydrogels for macromolecular drug delivery, J. Pharm. Pharmacol. 50 (Supp.): 171			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 19 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 579		Wilson et al., 1983, Precorneal drainage, of polyvinyl alcohol solutions in the rabbit assessed by gamma scinitgraphy, J. Pharm. Pharmacol. 35: 451-454			402-403			
DTX 580		Zaki et al., 1986, A comparison of the effect of viscosity on the precorneal residence of solutions in rabbit and man, J. Pharm. Pharmacol. 38: 463-466			402-403			
DTX 581		Fitzgerald and Wilson, 1994, Polymeric Systems for Ophthalmic Drug Delivery (Polymeric Biomaterials, S. Dumitriu ed, Marcel Dekker)			402-403			
DTX 582		K. Connors et al., 1979, Chemical Stability of Pharmaceuticals: A Handbook for Pharmacists (John Wiley & Sons)			402-403			
DTX 583		WO 0587202			402-403			
DTX 584		WO 0368843			402-403			
DTX 585		WO 0367952			402-403			
DTX 586		Literature Re: Kollidon and Povidone			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 20 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 587	12/17/04	Plaintiffs' Allergan, Inc. and Allergan Sales, LLC'S Answers to Defendants' First Set of Requests for Production of Documents and Things (Nos. 1-26)			402-403			
DTX 588	12/17/04	Plaintiffs Allergan, Inc. and Allergan Sales, LLC'S Responses to Defendants First Set of DTX Interrogatories (Nos. 1-11)			402-403			
DTX 589	01/13/05	Allergan, Inc. and Allergan Sales, LLC'S Response to Defendants' Second Set of Requests for Production of Documents and Things (Nos. 27-34)			402-403			
DTX 590	02/04/05	Allergan, Inc. and Allergan Sales, LLC'S Supplemental Responses to Defendants' Interrogatories Nos. 1-5			402-403			
DTX 591	03/22/05	Plaintiffs Allergan, Inc. and Allergan Sales, LLC's Supplemental Response to Defendants' Interrogatories Nos. 2 and 3			402-403			
DTX 592	05/06/05	Plaintiffs' Response to Defendants' First Set of Requests for Admissions (Nos. 1-26)			402-403			
DTX 593	05/06/05	Plaintiffs' Response to Defendants' Second Set of Interrogatories (No. 12)			402-403			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 21 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
DTX 594	05/12/05	Allergan, Inc. and Allergan Sales, LLC's Response to Defendants' Third Set of Requests for Production of Document and Things (Nos. 35-39)			402-403			
DTX 595	08/15/05	Allergan, Inc. and Allergan Sales, Ltd.'s Response to Alcon Inc.'s et al. Fourth Set of Requests for Production of Documents and Things (Nos. 40-41)			402-403			
DTX 596	08/15/05	Plaintiffs' Response to Defendants' Third Set of Interrogatories (Nos. 13-24)			402-403			
DTX 597		Vial of Alcon's Proposed Product Containing 0.15% Brimonidine Tartrate			402-403, 702-703, 901			
DTX 598		Supplemental Expert Report of Gordon Amidon			402, 403, 802, 702, 703, and F.R.C.P .37(c) and Scheduling Order			
DTX 599	01/17/06	Lab Notebook Page from Supplemental Expert Report of Gordon Amidon	ALC61348		402, 403, 802, 702, 703, and F.R.C.P .37(c) and Scheduling Order			
DTX 600	01/17/06	Brimonidine Tartrate HPLC Assay from Supplemental Expert Report of	ALC61349		402, 403, 802, 702, 703, and F.R.C.P			

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 22 of 23

TAB 5

ALLERGAN, INC., et al. v. ALCON, INC., et al.
Civil Action No. 04-968-GMS
PROPOSED SCHEDULE OF ALCON'S TRIAL EXHIBITS
January 17, 2006

Alcon hereby reserves the right to use any exhibit identified by either party. Alcon also reserves the right to amend the joint exhibit list upon further review of the documents listed on Allergan's schedule of proposed trial exhibits. Per the parties' agreement, Alcon will identify its demonstrative exhibits at a later date.

Defendant Exh. No.	Date of Document	Title or Description	Bates Numbers	Deposition Exhibit No.	Allergan Objection[1]	Alcon Objection	Identified	Admitted
		Gordon Amidon			.37(c) and Scheduling Order			
DTX 601		Demonstrative Exhibits						

Case 1:04-cv-00968-GMS Document 168-4 Filed 01/24/2006 Page 23 of 23